These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 9167419

  • 1. Doxazosin-alpha-1-adrenergic antagonists drug in the long-term (3 years). Management of benign prostatic hyperplasia.
    Dutkiewicz S.
    Mater Med Pol; 1996; 28(3):93-102. PubMed ID: 9167419
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia.
    Kirby RS.
    Br J Clin Pract Suppl; 1994 May; 74():23-8. PubMed ID: 7519438
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Doxazosin in the gastrointestinal therapeutic system (GITS) and doxazosin standard in patients with benign prostatic hyperplasia. Double-blind trial of efficacy and tolerability].
    Gratzke P, Kirby RS.
    Fortschr Med Orig; 2000 Jul 27; 118 Suppl 2():83-92. PubMed ID: 15700491
    [Abstract] [Full Text] [Related]

  • 7. Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice.
    Chung BH, Hong SJ, Lee MS.
    Int J Urol; 2005 Feb 27; 12(2):159-65. PubMed ID: 15733110
    [Abstract] [Full Text] [Related]

  • 8. A comparative study of: long-term alpha-1-blocker, Doxazosin therapy versus surgery in the treatment of benign prostatic hyperplasia.
    Dutkiewicz S.
    Mater Med Pol; 1995 Feb 27; 27(4):151-2. PubMed ID: 9000839
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA, Loran OB, Pushkar' DIu, Perepanova TS, Tevlin KP.
    Urol Nefrol (Mosk); 1998 Feb 27; (3):3-5. PubMed ID: 9644978
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. An economic evaluation of doxazosin, finasteride and combination therapy in the treatment of benign prostatic hyperplasia.
    McDonald H, Hux M, Brisson M, Bernard L, Nickel JC.
    Can J Urol; 2004 Aug 27; 11(4):2327-40. PubMed ID: 15380054
    [Abstract] [Full Text] [Related]

  • 16. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA, McVary KT.
    Int J Impot Res; 2008 Dec 27; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D, Soebadi DM, Sugandi S, Birowo P, Djati W, Wahyudi I.
    Int J Urol; 2006 Nov 27; 13(11):1405-9. PubMed ID: 17083392
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
    Kyprianou N.
    J Urol; 2003 Apr 27; 169(4):1520-5. PubMed ID: 12629407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.